Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
-- Market Launch Expected First Half of 2014 --
SEATTLE, Jan. 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. In November 2012, Omeros announced that OMS302 met the co-primary efficacy endpoints in this second pivotal Phase 3 clinical trial by demonstrating statistically significant (p<0.00001) maintenance of intraoperative mydriasis (pupil dilation) and statistically significant (p=0.0002) reduction of pain in the early postoperative period.
This multicenter, double-blind, Phase 3 clinical trial enrolled 416 patients randomized 1:1 to receive either OMS302 or placebo. Safety data were collected through postoperative day 90. In this Phase 3 clinical trial, OMS302 was well tolerated. The incidence of adverse events was similar between the two treatment groups, and the adverse event profile was similar to that seen in prior OMS302 clinical trials. No safety concerns have been identified in the OMS302 clinical development program. Results from this study are expected to be presented at an upcoming major ophthalmology meeting. Omeros also plans to publish the results in a leading peer-reviewed ophthalmology journal.
"While these data were expected, they underscore the safety benefits of intraoperative and local delivery of OMS302 – administration of efficacious and low concentrations of the active ingredients directly to the surgical site reduces systemic uptake and the probability of adverse side effects," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "Together with the strong and consistent efficacy data observed throughout its clinical development program, we believe that OMS302 represents a significant advance in lens replacement surgery, and our NDA and MAA are progressing well. We also expect to read out data from our OMS824 multiple-dose pharmacokinetic clinical trial later this quarter and to begin our second OMS103HP meniscectomy Phase 3 trial next quarter."
About Omeros' OMS302 Program
OMS302 is Omeros' product being developed for use during
intraocular lens replacement (ILR) surgery, including cataract
surgery and refractive lens exchange. OMS302 is a proprietary
combination of ketorolac, an anti-inflammatory agent, and
phenylephrine, a mydriatic (pupil dilating) agent. FDA-approved
drugs containing each of these agents have been used in
ophthalmological clinical practice for more than 15 years, and both
are contained in generic, FDA-approved drugs.
ILR surgery involves replacement of the original lens of the eye with an artificial intraocular lens. These procedures are typically performed to replace a lens opacified by a cataract or to correct a refractive error of the lens (i.e., refractive lens exchange). OMS302 is added to standard irrigation solution used in ILR surgery and delivered intracamerally to maintain intraoperative mydriasis (pupil dilation), to prevent surgically induced miosis (pupil constriction), and to reduce postoperative pain and irritation. Maintenance of mydriasis is critical to the safety and surgical ease of the procedure. Intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.
About Ophthalmological Procedures (Cataract and Other Lens
Replacement Surgery)
There are 3.6 million intraocular lens replacement procedures
expected in the U.S. this year and 15 million in developed
countries, with a projected annual growth rate of three to four
percent. There are multiple commercial opportunities within the
lens replacement market, including both standard and premium
lenses. The premium market includes toric, multifocal and
accommodating lenses. Refractive lens exchange is also a growing
segment of the lens replacement market.
About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to
discovering, developing and commercializing products targeting
inflammation, coagulopathies and disorders of the central nervous
system. The Company's most clinically advanced product candidates,
OMS302 for lens replacement surgery and OMS103HP for arthroscopy,
are derived from its proprietary PharmacoSurgery™ platform
designed to improve clinical outcomes of patients undergoing a wide
range of surgical and medical procedures. Omeros has five clinical
development programs. Omeros may also have the near-term
capability, through its GPCR program, to add a large number of new
drug targets and their corresponding compounds to the market.
Behind its clinical candidates and GPCR platform, Omeros is
building a diverse pipeline of protein and small-molecule
preclinical programs targeting inflammation, coagulopathies and
central nervous system disorders.
Forward-Looking Statements
This press release contains forward-looking statements as defined
within the Private Securities Litigation Reform Act of 1995, which
are subject to the "safe harbor" created by those sections. These
statements include, but are not limited to, Omeros' expectations
regarding the date of the expected market launch of OMS302, when it
will read out data from is OMS824 program and begin enrolling its
second OMS103HP Phase 3 trial, the growth rate of the number of
intraocular lens replacement procedures performed annually and that
Omeros may have capability, through its GPCR program, to add a
large number of new drug targets and their corresponding compounds
to the market. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management
only as of the date of this press release. Omeros' actual results
could differ materially from those anticipated in these
forward-looking statements for many reasons, including, without
limitation, the risks, uncertainties and other factors described
under the heading "Risk Factors" in the Company's Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission on
November 9, 2012. Given these risks, uncertainties and other
factors, you should not place undue reliance on these
forward-looking statements, and the Company assumes no obligation
to update these forward-looking statements publicly, even if new
information becomes available in the future.
SOURCE Omeros Corporation
CONTACT: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor and Media Relations, +1-360-668-3701, jennifer@cwcomm.org
Posted: January 2013
